---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-005060"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T22:44:56.093308+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Bio-Path expands global patent portfolio with new patents in Mexico, Australia, Japan

## Summary
- Received newly issued patents in Mexico (IGF-1R inhibition), Australia (STAT3, IGF-1R, BCL2 inhibition), and Japan (liposomal formulation).
- Portfolio now includes 5 issued US patents and 54 foreign patents covering 21 countries.
- Expects six additional patent grants this year; 51 pending applications across six families.
- Patents protect DNAbilize antisense platform and provide 20 years of exclusivity for new targets.

## SEC filing metadata
- accession: 0001558370-24-005060
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837024005060/0001558370-24-005060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837024005060/bpth-20240415x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-005060
- JSON: https://secwatch.observer/filing/0001558370-24-005060.json
- Plain text: https://secwatch.observer/filing/0001558370-24-005060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.